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Abstract
Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and
disinfectants in treating bacterial vaginosis (BV).
Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (19702010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics
and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A.
Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was
assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if
diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria.
Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four
randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of
standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard
antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for
assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide
compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide
was slightly, though significantly less effective than a single oral dose of metronidazole.
Conclusion: The use of antiseptics and disinfectants for the treatment of BV has been poorly studied and most
studies are somehow methodologically flawed. There is insufficient evidence at present to advocate the use of
these agents, although some studies suggest that some antiseptics may have equal efficacy compared to
clindamycin or metronidazole. Further study is warranted with special regard to the long-term efficacy and safety of
antiseptics and disinfectants for vaginal use.
Keywords: Bacterial vaginosis, Antiseptics, Disinfectants, Therapy, Systematic review, Chlorhexidine,
Polyhexamethylene biguanide, Hydrogen peroxide

Background
Bacterial vaginosis (BV) is a condition characterised by
the partial loss of the indigenous vaginal lactobacilli
coupled with polymicrobial anaerobic overgrowth of the
vaginal epithelium. Although BV often remains asymptomatic, it is one of the most common causes of vaginitis, and hence among the most common reasons for
women to seek medical help [1] In recent years BV has
further emerged as a global issue of concern due to its
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association with ascending genital tract infection and
with sexually transmitted infections [2].
Current recommendations by the Centres for Disease
Control and Prevention (CDC) for the treatment of BV
basically involve antibiotic treatment with oral or intravaginal metronidazole or clindamycin [3]. Although
these treatment modes are associated with fairly good
short-term cure rates, they fail to prevent BV in at least
half of the cases in the long run [4]. Several alternative
treatment approaches are therefore being (re)considered,
including the use of antiseptics and disinfectants.
Antiseptics have been used for over half a century in the
treatment of vaginal infections. Similar to antibiotics,
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antiseptics facilitate the eradication of the anaerobic vaginal microbiota associated with bacterial vaginosis which
allows for the recolonisation of indigenous lactobacilli.
Antiseptics generally have a very broad spectrum as they
act non-specifically on bacteria through mechanisms such
as bacterial cell membrane disruption. In accordance,
there are very few reports on antimicrobial resistance to
these agents. Nonetheless, antiseptics and disinfectants
have become unpopular for the purpose of treating vaginal
infections, presumably because they are often used as
over-the-counter (OTC) products associated with vaginal
douching, a common practice that has been associated
with the occurrence of BV. In many countries, antiseptics
are still marketed for the treatment of vaginal infections,
though their efficacy has not been supported by a sound
evidence base. We therefore sought to assess currently
available data on the efficacy and tolerability of antiseptics
and disinfectants in the treatment of BV. Through a systematic literature search, we identified and evaluated clinical trials that compared antiseptic and/or disinfectant
treatment to either placebo or standard antibiotic treatment in women of any age.

Methods
Objectives

The overall objective is to summarize currently available
data (published up to December 31 2010) on the efficacy
and tolerability of antiseptics and disinfectants in the treatment of BV, thereby accounting for the quality of the clinical trials identified through a systematic literature search.
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mercuric amidochloride, phenylmercuric borate, mercuric
chloride, mercurochrome, mercury, thiomersal, mercuric
iodide, phenylmercuric borate, silver nitrate, silver, hydrogen peroxide, eosin, propanol, tosylchloramide sodium,
isopropanol, potassium permanganate, sodium hypochlorite, and ethanol.
In addition we accounted for benzydamine which is
listed under ATC code G02CC03 for “anti-inflammatory
products for vaginal administration”, considering benzydamine also has broad antimicrobial activity.
Only English-language studies were considered for review. Additional studies were searched for by checking
cross-references cited in the primary studies. No efforts
were made to identify unpublished studies.
Types of studies

Reports were considered eligible if they involved clinical
trials in which the efficacy and tolerability of antiseptics
and disinfectants in the treatment of BV was assessed in
comparison to placebo or in comparison to standard
antibiotic treatment with metronidazole or clindamycin.
Studies were considered eligible if at least 40 study
participants had been enrolled for comparison between
the two treatment arms.
Types of participants

Women of any age diagnosed with bacterial vaginosis
through standardized criteria like Amsel’s or Nugent
criteria [5,6]. No study was excluded because of (possible) co-infection with sexually transmitted infections.

Search strategy

An electronic search was conducted by consulting the
following databases: PubMed (1966-2010), CINAHL
(1982-2010), International Pharmaceutical Abstracts
(IPA) database (1970-2010), and the Cochrane Central
Register of Controlled Trials.
Clinical trials were searched for by use of the key words
“bacterial vaginosis” and “non-specific vaginitis” in combination with “disinfectant”, “antiseptic”, and subsequently with all generic names of antiseptics and
disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A
(Antiseptics and disinfectants), i.e. ethacridine lactate,
aminoacridine, euflavine, aluminium agents, dibrompropamidine, chlorhexidine, propamidine, hexamidine, polyhexanide, boric acid, hexachlorophene, policresulen,
phenol, triclosan, chloroxylenol, biphenylol, nitrofural,
iodine/octylphenoxypolyglycolether, povidone-iodine, iodine, diiodohydroxypropane, dequalinium, chlorquinaldol,
oxyquinoline, clioquinol, benzalkonium, cetrimonium,
cetylpyridinium, cetrimide, benzoxonium chloride, didecyldimethylammonium chloride, benzethonium chloride,
octenidine, benzethonium chloride, dodeclonium bromide,

Types of intervention

We confined our review to antiseptics and disinfectants for
which the dosage and treatment regimen was specified, and
which are listed in the Anatomical Therapeutic Chemical
(ATC) Classification System under the code D08A (“antiseptics and disinfectants”). In addition we accounted for
benzydamine which is listed under ATC code G02CC03 for
“anti-inflammatory products for vaginal administration”,
considering benzydamine also has broad antimicrobial activity. Hence, we excluded any report in which any antiseptic product (e.g. herbal medicines) was used for which the
chemical composition and/or substance dose was not verifiable. Treatment with an antiseptic or disinfectant was considered in any preparation type, any dosage regimen, and
any route of administration.
Types of outcome measures

The primary outcome was cure of bacterial vaginosis as
assessed through use of the Amsel criteria or Nugent
criteria at least 7 days following treatment initiation.
Cure was defined as a Nugent score <7 or the presence
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of less than 3 Amsel criteria. The secondary outcome was
the occurrence of adverse reactions or side effects, with
special regard to vaginal symptoms following local administration of antiseptics.

octenidine (1 RCT), polyhexamethylene biguanide (2
RCTs), and povidone iodine (6 clinical trials including
5 RCTs). These studies are herewith listed and briefly
discussed according to the antiseptic or disinfectant
under study.

Risk of bias in included studies

As indicated by the PRISMA guidelines no efforts were
made to label the quality of studies in a (semi-)quantitative
matter [7]. Rather, the Cochrane Collaboration tool for
assessing risk of bias was applied to assess the risk of various sources of bias among the included studies [8].

Results
Through the Boolean search of the electronic
databases PubMed, CINAHL, IPA, and Cochrane
CENTRAL, a total of 262 articles on BV and antiseptics and disinfectants were identified. Two additional articles were retrieved during the background
literature study [9,10]. Eventually, 15 full-text papers
were assessed for eligibility. Of these, four randomised controlled trials (RCTs) met the inclusion criteria set forth. The search and selection strategy is
presented as a PRISMA flow diagram in Figure 1.
The 15 clinical trials identified involved treatment
with one or more of the following antiseptics and disinfectants: benzydamine (2 RCTs), chlorhexidine
(2 RCTs), dequalinium chloride (1 RCT), hydrogen
peroxide (3 clinical trials including 1 RCT),

Records identified through
database searching
(n = 262)

Benzydamine

We found two randomized clinical trials on treatment of
BV with benzydamine of which none was in accordance
with the inclusion criteria set forth [10,11].
In the 1987 double-blinded randomised controlled trial
by Ventolini et al. [11] a regime of intravaginal 0.1% benzydamine hydrochloride applied twice daily for 10 days was
compared nor to placebo, neither to standard antibiotic
treatment. In addition no standard criteria were applied for
the diagnosis of BV neither at recruitment nor at follow-up.
Hence we considered this study not assessable for the purpose of the present study.
Hay et al. conducted a small double-blinded randomised
controlled trial in which 15 patients were enrolled of which
8 used 140 ml of 0.1% benzydamine vaginal douche twice a
day for 7 days and 7 patients applied a similar regimen with
placebo douches [10]. Diagnosis of BV was made through
Amsel criteria and Nugent score at enrolment and cure
was defined as a normal Gram stain and absence of clue
cells on wet mount. Since the sample size was below the
lower limit set forth, we did not include the study.

Additional records identified
through other sources
(n = 2)

Records after duplicates removed
(n = 245)

Records screened
(n = 245)

Records excluded (articles
did not report on RCTs)
(n = 230)

Full-text articles assessed
for eligibility
(n = 15)

Full-text articles excluded
(studies not in accordance
with study protocol)
(n = 11)

Studies included in
qualitative synthesis
(n = 4)

Figure 1 Literature search and selection process (PRISMA Flow Diagram).
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Table 1 Main characteristics of included studies
Reference

Experimental
treatment

Ison 1987

pessary containing
single 2 g oral dose of
150 mg chlorhexidine metronidazole
for 2 consecutive nights

Molteni 2004

chlorhexidine
vaginal gel
(2.5 g chlorhexidine
per dose)
applied for
seven days

Control treatment

Duration
Method
of follow-up applied to
assess cure

Cure rates

Risk ratio
(95% CI, p-value)

7 days

36/43 versus
28/36

1.08 [0.86; 1.34],
p = 0.5

14/27
versus
15/25

1.16 [0.71; 1.88],
p = 0.6
0.79 [0.57; 1.08],
p = 0.06

Amsel
criteria

28 days

500 mg metronidazole 28 days
vaginal tablet daily for
seven days

Amsel
criteria

28/30 versus
11/15

Chaithongwongwatthana a single hydrogen
2003
peroxide vaginal
douche/placebo
tablets similar to
the metronidazole
tablets

4 tablets of 500 mg
14 days
metronidazole/placebo
vaginal douche
with clean
water

Amsel
criteria

45/72 versus 55/70 1.26[1.01; 1.56],
p = .036

Minozzi 2008

2% clindamycin
cream for
7 days

Amsel criteria 153/175 versus
and Nugent 143/172 (Amsel)
score

0.95
[0.87; 1.04],
p = 0.3

99/175 versus
99/172 (Nugent)

1.02
[0.85; 1.22],
p = 0.9

single dose of 100 ml
of a 10%
polyhexamethylene
biguanide vaginal
gel solution

Chlorhexidine

We identified two single-blinded randomised controlled
trials in which the efficacy of vaginally administered chlorhexidine with a chlorhexidine-containing pessary [12] and
a chlorhexidine-based vaginal gel respectively [13] was
compared to treatment of BV with metronidazole.
In the 1987 study by Ison et al. [12] 79 women attending
an outpatient London clinic and diagnosed with BV according to Amsel’s criteria were enrolled, two thirds of which
had a history of recurrent vaginosis. Women were randomised (randomisation procedure and allocation concealment not specified) to receive either a single pessary
containing 150 mg chlorhexidine for two consecutive
nights (n = 43), or a single 2 g oral dose of metronidazole
(n = 36). Upon blinded reassessment after seven days, 84%
of women in the chlorhexidine arm were found to be negative for all Amsel criteria, as were 78% of women in the
metronidazole group (see Table 1). Sixty-three out of the 79
study participants were again evaluated in a blind manner
at 28 days, and cure rates according to Amsel’s criteria were
52 and 60% in the chlorhexidine and metronidazole group
(see Table 1), respectively. No mention is made of any adverse effects in this report.
In the 2004 multicentre Italian study by Molteni et al.
[13], 90 women were enrolled in four outpatient gynaecology services and one STD clinic, half of which who
were diagnosed with Candida vaginitis, the other half
being diagnosed with BV according to Amsel’s criteria.
Women with BV (n = 45) were randomised according to

21 to
30 days

a computer-generated randomisation scheme in a 2 to 1
ratio (allocation concealment not specified) with 30
women being assigned to the treatment group with
chlorhexidine vaginal gel (2.5 g chlorhexidine per dose)
applied for seven days and 15 women serving as controls
taking a 500 mg metronidazole vaginal tablet daily for
seven days. At week 4, blinded reassessment according
to Amsel showed a cure rate of 93% in the chlorhexidine
group compared to a 74% cure rate in the metronidazole
group (see Table 1). With regard to side effects, Molteni
et al. recorded that no serious adverse events were
observed and that no women complained of vaginal discharge after treatment. In the experimental arm, overall
six women (20%) complained of mild transient burning
after chlorhexidine vaginal gel application.
Dequalinium chloride

We found no controlled trials in which the efficacy of
intravaginal dequalinium chloride in treating BV was
compared to placebo or to standard antibiotic treatment.
We did identify one large single-blinded, randomised
controlled trial in which the efficacy of dequalinium
chloride was weighed against that of povidone-iodine in
treating BV [14].
Hydrogen peroxide

We identified two non-controlled clinical trials that we
excluded from this review [15,16], and one randomised
triple-blinded controlled trial in which the efficacy of
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vaginal hydrogen peroxide instillation in curing BV was
assessed [17].
In a very well-designed triple-blinded randomised controlled trial, Chaithongwongwatthana et al. investigated
the effectiveness and safety of a single hydrogen peroxide vaginal douche in treating bacterial vaginosis [17]. In
this study, 142 patients with BV were enrolled in a Thai
outpatient gynaecologic clinic. Diagnosis was made
according to Amsel’s criteria. Randomisation relied on
computer-generated random number scheme and both
subjects and investigators were blinded to treatment. In
addition double dummies were used to ensure blinding.
In the experimental treatment arm patients (n = 72) were
treated with a single douche with 20 ml of a 3% hydrogen peroxide solution in lithotomy position for 3 minutes, whereas in the control arm patients (n = 70)
received 4 tablets of 500 mg metronidazole. The dummy
treatments consisted of a vaginal douche with clean
water in the metronidazole group and of identical placebo tablets similar to the metronidazole tablets in the
hydrogen peroxide group. Follow-up was performed at
2 weeks following treatment. Cure was defined as the
absence of at least 3 Amsel criteria. Assessors were
blinded for the treatment allocation. The cure rates were
62.5% in the hydrogen peroxide group and 78.6% in the
metronidazole group (see Table 1). Patients in the
metronidazole group had significantly more gastrointestinal side effects (48.6% versus 13.9%, p < 0.001), whereas
patients in the hydrogen peroxide group had significantly more mild vaginal irritation (33.3% versus 14.3%,
p = 0.008).
Octenidine

In a large Serbian RCT, the efficacy of an octenidine
hydrochloride/phenoxyethanol spray as compared to
standard treatment with 500 mg metronidazole vaginal
tablets for 7 days was assessed among 450 patients enrolled in an outpatient gynecology clinic and diagnosed
with BV according to Amsel’s criteria [18]. Unfortunately, the authors did not specify how cure was defined.
In particular, the authors state that study participants
were “examined gynecologically” and that “control
smears were taken for further bacteriologic analysis”
[18]. We therefore repeatedly tried to contact the
authors with a request for more detailed information;
however we did not get any response. The otherwise
very well designed study could therefore not be
included.
Polyhexamethylene biguanide

We identified two controlled clinical trials on treatment
of BV with polyhexamethylene biguanide [19,20], a biguanide antiseptic that is actually listed in the Anatomical Therapeutic Chemical (ATC) Classification System
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as polyhexanide. One study was considered not assessable [19], whereas another large study was withheld [20].
In the 2003 single-blinded randomised controlled trial
by Gerli et al., 133 patients were enrolled of which 59
received a 2% polyhexamethylene biguanide gel solution
and 51 administered 2% clindamycin cream for 7 days
[19]. However, neither at enrolment nor at follow-up
were all patients systematically assessed through Amsel’s
or Nugent’s criteria and therefore we consider the study
not assessable to the purpose of the present study.
The 2008 study by Minozzi et al. was a multi-centred
single (investigator)-blinded randomised controlled trial
in which 740 BV patients were enrolled [20]. Patients
were considered eligible if they fulfilled all Amsel’s criteria and were then randomly assigned to one of two
treatment arms, i.e. a single dose of 100 ml of a 10%
polyhexamethylene biguanide vaginal gel solution
(n = 371) or 2% clindamycin cream for 7 days (n = 369).
Patients were then re-assessed through Amsel’s and
Nugent’s criteria at 21 to 30 days following treatment
initiation. Eventually data on 347 patients were evaluable; this is 46.9% of patients constituting the inception
cohort. Hence, although attrition was high, the authors
gave a detailed description for non-inclusion in the final
per protocol analysis for 147 of the 196 non-included
patients in the polyhexamethylene biguanide group and
for of all 197 non-included patients in the clindamycin
group. Cure was defined among others as the absence of
all four, of three and of two of the Amsel’s criteria and
was obtained in 64.3, 87.5, and 90.6% versus 63.2, 83.2,
and 91.2% patients in the polyhexamethylene biguanide
and clindamycin groups respectively (see Table 1). Reconversion to a normal microbiota (Nugent score <4)
was achieved in 56.5 and 57.7% (see Table 1) of patients
in the polyhexamethylene biguanide and clindamycin
groups, while absence of clue cells was recorded in 87.5
and 84.0%, respectively. Thirty-seven patients in the
polyhexamethylene biguanide group reported 29 study
medication-related adverse events (AEs) compared to 29
patients in the clindamycin group who reported 22 study
medication-related AEs (P = 0.3).
Povidone iodine

We found six clinical trials in which povidone iodine
was evaluated for its efficacy in the treatment of BV.
One trial was a non-controlled study [21]. One study
entailed a comparison with benzydamine [11], another
study involved a comparison with dequalinium chloride
[14], and a third one compared povidone iodine to a
probiotic [22]. The remainder of studies were two
placebo-controlled studies [9,23].
In the 1982 study by Dattani et al. patients were randomised to use either a 200 mg povidone-iodine containing pessary either an identical looking placebo
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pessary during night and morning for two weeks [23].
As no standard criteria (Amsel’s criteria or Nugent criteria) in this era were used either at inclusion or at follow-up, this study was discarded.
Van der Meijden et al. [9], also compared a 200 mg
povidone-iodine containing pessary inserted into the vagina in the morning and evening for 5 consecutive days
with placebo pessaries. As no standard criteria (Amsel’s
criteria or Nugent criteria) in this era were used at inclusion or at follow-up, this study was therefore also considered not assessable.
In summary, of the 15 clinical trials identified through
a systematic literature search, merely four RCTs with at
least 40 study participants involved the comparison of a
vaginal antiseptic to placebo or to standard antibiotic
treatment and thereby relied on standard criteria in
assessing BV and cure rates. Main characteristics of the
latter studies are displayed in Table 1.
The four selected RCTs compared antiseptics to
metronidazole or clindamycin. In two studies control
treatment consisted of a single oral dose of 2 g metronidazole, in one study of a 7-day regime of 500 mg
metronidazole intravaginally, and in one study of 2%
clindamycin cream for 7 days. Only the latter two treatment modes are CDC recommended regimens [3].
Three studies showed non-inferiority of the antiseptics
applied in comparison to antibiotic treatment. In one
study, a single douche with 20 ml of a 3% hydrogen peroxide was significantly less effective than a single 2 g
oral dose of metronidazole.
Only one RCT was double-blinded (and actually
triple-blinded) through the use of double dummies [17].
Randomisation procedure was reported to involve a
computer-generated random number series in two studies [13,17]. Allocation concealment was not mentioned
explicitly in any study, except one [17]. As to selection
bias, in none of the studies it was actually explicitly
reported that consecutive patients were enrolled. In one
large trial, attrition was very high albeit welldocumented [20]. Follow-up ranged from 7 up to
28 days. In one out of the four RCTs no mention is
made of recording of side effects [12]. Risk of selection,
performance, detection, attrition, and reporting bias was

assessed through use of the Cochrane Collaboration tool
for assessing risk of bias [8] and is presented in Table 2.
With regard to side-effects, no mention is made of any
adverse effects in the study on the chlorhexidine pessary
[12]. In the study on chlorhexidine gel [13] it was merely
mentioned that, overall, six women (20%) complained of
mild transient burning after chlorhexidine vaginal gel
application. In the hydrogen peroxide trial [17], patients
in the metronidazole group had significantly more
gastrointestinal side effects (48.6% versus 13.9%,
p < 0.001), whereas patients in the hydrogen peroxide
group had significantly more mild vaginal irritation
(33.3% versus 14.3%, p = 0.008). Finally, in the polyhexamethylene biguanide study [20] it was reported that
thirty-seven patients in the polyhexamethylene biguanide group (10.3%) reported 29 study medication-related
adverse events (AEs) compared to 29 patients in the
clindamycin group (7.9%) who reported 22 study
medication-related AEs and that the number of patients
who reported AEs and study medication-related AEs
were not statistically different between the two groups
(P = 0.386 and 0.336 respectively). A detailed overview of
AEs was given in this report and no significant differences were observed for any given AE, including vaginal
symptoms. So, overall in two of the three studies that
reported AEs elevated rates of vaginal irritation or burning were recorded.

Discussion
We sought to assess and summarize currently available
data on the efficacy and tolerability of antiseptics and
disinfectants in treating BV. Overall, we identified 15
clinical trials that dealt with treatment of BV with antiseptics and disinfectants. Taking into account the limitations of the studies, it was found that some of the
antiseptics tested, i.e. chlorhexidine and polyhexamethylene biguanide were equally effective to antibiotic treatment, whereas in one study, a single douche of hydrogen
peroxide was slightly, though significantly less effective
than a single 2 g oral dose of metronidazole.
Eleven studies were discarded, because the studies had
no RCT design, because diagnosis of BV at inclusion

Table 2 Risk of bias for included studies
Ison 1987

Molteni 2004

Chaithongwongwatthana 2003

Minozzi 2008

Random sequence generation

?

+

+

?

Allocation concealment

?

?

+

?

Blinding of participants and personnel

-

-

+

-

Blinding of outcome assessment

+

+

+

?

Incomplete outcome data

-

+

+

-

Selective reporting

+

+

+

+

Legend. + indicates low risk of bias, - indicates high risk of bias, and ? indicates unknown risk of bias.
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and/or on follow-up did not rely on standard criteria like
Amsel’s or Nugent’s criteria, or because the control
treatment arm did not involve placebo or standard antibiotic treatment.
Of the four studies included, only one RCT was
double-blinded (and actually triple-blinded) through the
use of double dummies. Risk of selection bias and of
performance bias was generally high. Risk of attrition
bias was high in one study. Reporting bias was presumably low. It should be added that the risk of publication
bias is also presumably high, especially since published
reports often involved commercial antiseptic products
marketed for vaginal use.
Follow-up in all studies was limited, as has previously
been noted with antibiotic treatment studies on BV [4].
Hence, it remains unclear at present whether antiseptics
and disinfectants might offer an alternative to the poor
long-term cure rates observed with clindamycin and
metronidazole. On the other hand, antiseptics and disinfectants might be better suited for repeated treatment
courses than antibiotics, one reason being the odds of
antibacterial resistance occurring, as has been observed
with clindamycin for instance [24,25].
Another issue of concern that has been insufficiently
addressed at present is the safety of the antiseptic products and their excipients used. While one of the four
studies we withheld for qualitative analysis did not make
any mention of side effects, two of the three studies that
reported adverse events reported increased rates of vaginal irritation or burning.
Though some agents like chlorhexidine and povidone
iodine have been widely used for preoperative wound
prophylaxis and have also been studied for perpartum
GBS prophylaxis and as microbicides, we believe that
the safety of these agents especially upon repeated use
warrants further scrutiny. This is particularly important
considering in many parts of the world women with BV
are often also at elevated risk for HIV acquisition and
since HIV infection may be enhanced when epithelial integrity is threatened by local products.

Conclusions
It may be concluded that the use of antiseptics and disinfectants for the treatment of BV has been poorly studied and that most studies that did address the subject
are somehow methodologically flawed. Limited data indicate that some antiseptics may have equal efficacy in
treating BV on short term compared to treatment with
clindamycin or metronidazole. Further study is however
warranted with special regard to long-term efficacy and
safety of antiseptics and disinfectants for vaginal use.
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